# Scleroderma Lung Study III - Combining Pirfenidone With Mycophenolate

> **NCT03221257** · PHASE2 · COMPLETED · sponsor: **Michael Roth** · enrollment: 51 (actual)

## Conditions studied

- Scleroderma, Systemic
- Interstitial Lung Disease

## Interventions

- **DRUG:** Pirfenidone (PFD)
- **DRUG:** Placebo (Plac)
- **DRUG:** Mycophenolate Mofetil (MMF)

## Key facts

- **NCT ID:** NCT03221257
- **Lead sponsor:** Michael Roth
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-28
- **Primary completion:** 2022-03-23
- **Final completion:** 2022-06-13
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2023-12-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03221257

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03221257, "Scleroderma Lung Study III - Combining Pirfenidone With Mycophenolate". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03221257. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*